The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.38
Bid: 2.21
Ask: 2.47
Change: 0.00 (0.00%)
Spread: 0.26 (11.765%)
Open: 2.38
High: 0.00
Low: 0.00
Prev. Close: 2.38
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Extension of warrants in Incanthera plc

21 Aug 2023 07:00

RNS Number : 8432J
Immupharma PLC
21 August 2023
 

21 August 2023

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

 

Extension of Warrants in Incanthera plc

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Company has agreed with Incanthera plc ("Incanthera") that Warrants issued to the Company on 26 February 2020, in conjunction with Incanthera's IPO onto the Aquis Exchange, are extended by 12 months.

 

Key highlights:

 

· The Company entered into a Warrant Instrument ("Warrant Instrument") with Incanthera on 26 February 2020, whereby Incanthera created and issued Warrants to ImmuPharma to subscribe in cash at £0.095 per share, for 7,272,740 Ordinary Shares, valid until 6 September 2023.

 

· Incanthera has agreed with the Company to extend the Warrant Instrument by 12 months to 6 September 2024.

 

· All other provisions in the Warrant Instrument remain the same.

 

· No consideration is being paid by ImmuPharma to obtain the extension.

 

ImmuPharma currently owns 9,904,319 shares in Incanthera (representing 12.7% of its issued share capital). In addition, Tim McCarthy, ImmuPharma's Chairman, is also the Chairman of Incanthera and has a holding of 3,931,646 shares (5.05%).

 

The Board of ImmuPharma has determined to treat the extension of the Warrants as a related party transaction. Mr McCarthy has not been involved in the ImmuPharma Board's decision to agree to the extension.

 

The Directors (excluding Mr McCarthy), having consulted with SPARK, the Company's nominated adviser, consider that the terms of the Warrant extension are fair and reasonable insofar as the Company's shareholders are concerned.

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim Franklin, Chief Operating Officer

Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

 

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 650 3650

 

 

+44 (0) 1483 413500

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk.

 

 

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSFESAUEDSEDA
Date   Source Headline
7th Feb 20077:01 amRNSBoard Changes
19th Jan 20078:57 amRNSTotal Voting Rights
5th Jan 20072:27 pmRNSIssue of Equity
27th Dec 20062:53 pmRNSTotal Voting Rights
21st Dec 20067:01 amRNSIssue of Equity
30th Oct 20067:01 amRNSFurther Phase II Data
17th Oct 20067:00 amRNSPhase II Data
2nd Oct 20067:01 amRNSFDA Meeting on Lupus
26th Sep 20067:01 amRNSInterim Results
1st Aug 20067:01 amRNSPreliminary Results
5th Jul 20067:00 amRNSStart of phase II trial
12th Jun 20065:04 pmRNSAccounting reference dates
10th May 20067:00 amRNSPhase 1 Lupus results
11th Apr 20067:00 amRNSResearch Grants
15th Feb 20061:56 pmRNSResult of EGM and Placing
24th Jan 20064:30 pmRNSSch 1 Update - ImmuPharma plc
23rd Jan 20064:27 pmRNSCirc re. ImmuPharma posted
30th Nov 20051:38 pmRNSInterim Results
27th May 20051:29 pmRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.